Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage

Blood

Volumn 98, Issue 13, 2001, Pages 3762-3769

  Mahieux, Renaud ^a,b,c   Pise Masison, Cynthia ^a,b   Gessain, Antoine ^a,b   Brady, John N ^a,b   Olivier, René ^a,b   Perret, Emmanuelle ^a,b   Misteli, Tom ^a,b   Nicot, Christophe ^a,b  

^a Institut Pasteur   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE 3; CASPASE 3 INHIBITOR; CYTOCHROME C; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL IMMORTALIZATION; CELL NUCLEUS; CELL SORTER; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME RELEASE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T CELL LEUKEMIA; T LYMPHOCYTE;

EID: 0035895082     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3762     Document Type: Article

References (61)

1. Takatsuki K, Yamaguchi K, Kawano F, et al. Clinical aspects of adult T-cell leukemia/lymphoma (ATL). Princess Takamatsu Symp. 1994;15:51-57.
2. Cereseto A, Kislyakova T, Washington Parks R, Nicot C, Franchini G. Differential response to genotoxic stress in immortalized or transformed human T-lymphotropic virus type I-infected T-cells. J Gen Virol. 1999;80:1575-1581.
3. Hermine O, Wattel E, Gessain A, Bazarbachi A. Adult T cell leukemia: a review of established and new treatments. BioDrugs. 1998;10:447-462.
4. Lau A, Nightingale S, Taylor GP, Gant TW, Cann AJ. Enhanced MDR1 gene expression in human T-cell leukemia virus-I-infected patients offers new prospects for therapy. Blood. 1998;91:2467-2474.
5. Ikeda K, Oka M, Yamada Y, et al. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer. 1999;82:599-604.
6. Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 1998;91:3935-3942.
7. Bazarbachi A, Nasr R, El-Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia. 2000;14:716-721.
8. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-1751.
9. Fujimura S, Suzumiya J, Anzai K, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res. 1998;22:611-618.
10. Maeda Y, Miyatake J, Sono H, et al. 13-cis retinoic acid inhibits growth of adult T cell leukemia cells and causes apoptosis: possible new indication for retinoid therapy. Intern Med. 1996;35:180-184.
11. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type 1-transformed cells. Blood. 1999;93:278-283.
12. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol. 1998;103:721-728.
13. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I-transformed cells is associated with tax down-regulation and reversal of NF-κB activation. Blood. 2000;96:2849-2855.
14. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
15. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev. 2000;64:821-846.
16. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
17. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp. 1999;66:1-15.
18. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419.
19. Cheng EH, Kirsch DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 1997;278:1966-1968.
20. Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem. 1999;274:21155-21161.
21. Tsukahara T, Kannagi M, Ohashi T, et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-κB in apoptosis-resistant T-cell transfectants with Tax. J Virol. 1999;73:7981-7987.
22. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood. 2000;96:275-281.
23. Li XH, Gaynor RB. Regulation of NF-κB by the HTLV-1 Tax protein. Gene Expr. 1999;7:233-245.
24. Rosin O, Koch C, Schmitt I, et al. A human T-cell leukemia virus Tax variant incapable of activating NF-κB retains its immortalizing potential for primary T-lymphocytes. J Biol Chem. 1998;273:6698-6703.
25. Grassmann R, Berchtold S, Radant I, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol. 1992;66:4570-4575.
26. Grassmann R, Fleckenstein B, Desrosiers RC. Viral transformation of human T lymphocytes. Adv Cancer Res. 1994;63:211-244.
27. Yoshida M. HTLV-1 Tax: regulation of gene expression and disease. Trends Microbiol. 1993;1:131-135.
28. Mesnard JM, Devaux C. Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Virology. 1999;257:277-284.
29. de La Fuente C, Santiago F, Chong SY, et al. Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol. 2000;74:7270-7283.
30. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell. 1998;93:81-91.
31. Kawakami A, Nakashima T, Sakai H, et al. Inhibition of caspase cascade by HTLV-I tax through induction of NF-κB nuclear translocation. Blood. 1999;94:3847-3854.
32. Pise-Masison CA, Choi KS, Radonovich M, et al. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol. 1998;72:1165-1170.
33. Santiago F, Clark E, Chong S, et al. Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells. J Virol. 1999;73:9917-9927.
34. Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p161NK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15:1607-1614.
35. Yamato K, Oka T, Hiroi M, et al. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-I-infected cells. Jpn J Cancer Res. 1993;84:4-8.
36. Philpott SM, Buehring GC. Defective DNA repair in cells with human T-cell leukemia/bovine leukemia viruses: role of tax gene. J Natl Cancer Inst. 1999;91:933-942.
37. Lemoine FJ, Kao SY, Marriott SJ. Suppression of DNA repair by HTLV type 1 tax correlates with tax trans-activation of proliferating cell nuclear antigen gene expression. AIDS Res Hum Retroviruses. 2000;16:1623-1627.
38. Nicot C, Harrod R. Distinct p300-responsive mechanisms promote caspase-dependent apoptosis by human T-cell lymphotropic virus type 1 Tax protein. Mol Cell Biol. 2000;20:8580-8589.
39. Kitajima I, Shinohara T, Bilakovics J, et al. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. Science. 1992;258:1792-1795.
40. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem. 2000;275:36062-36066.
41. Roussel RR, Barchowsky A. Arsenic inhibits NF-κB-mediated gene transcription by blocking IκB kinase activity and IκBα phosphorylation and degradation. Arch Biochem Biophys. 2000;377:204-212.
42. Mahieux R, Pise-Masison CA, Nicot C, et al. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses. 2000;16:1677-1681.
43. Mahieux R, Lambert PF, Agbottah E, et al. Cell cycle regulation of human interleukin-8 gene expression by the human immunodeficiency virus type 1 Tat protein. J Virol. 2001;75:1736-1743.
44. Pise-Masison CA, Mahieux R, Jiang H, et al. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-κB pathway and is dependent on p53 phosphorylation. Mol Cell Biol. 2000;20:3377-3386.
45. Webster GA, Perkins ND. Transcriptional crosstalk between NF-κB and p53. Mol Cell Biol. 1999;19:3485-3495.
46. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597-608.
47. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43.
48. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
49. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol. 1999;187:127-137.
50. 3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
51. 3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345-3353.
52. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052-1061.
53. Sternsdorf T, Puccetti E, Jensen K, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol. 1999;19:5170-5178.
54. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999;91:772-778.
55. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML- and PML-RARα-independent manner. Blood. 1998;92:1497-1504.
56. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
57. Reid RL, Lindholm PF, Mireskandari A, Dittmer J, Brady JN. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene. 1993;8:3029-3036.
58. Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A, Arima T. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines. Leuk Lymphoma. 2000;37:649-655.
59. Andrews JM, Oglesbee MJ, Trevino AV, et al. Enhanced human T-cell lymphotropic virus type I expression following induction of the cellular stress response. Virology. 1995;208:816-820.
60. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-KB in primary adult T-cell leukemia cells. Blood. 1999;93:2360-2368.
61. Tsukasaki K, Tomonaga M. Atra, NF-κB and ATL. Leuk Res. 2001;25:407-408.